SMCI - Accounting & Capital Structure Concerns | Equity Insights
- Reported earnings are GAAP-real but do not convert to cash, and the gap is widening. SMCI reported USD 1.05bn of net income across the first nine months of FY26 while consuming USD 7.56bn of operating cash flow. The cumulative accrual gap of USD 8.61bn against average total assets of USD 18.7bn implies a Sloan accrual ratio of approximately 46%, a level the academic accounting literature associates with elevated risk of future earnings reversal and which sits in the historical top <1% percentile of US large-cap readings.
- The Q2 FY26 working capital lever reversed in Q3 FY26 and the cash conversion cycle has tripled. Accounts payable expanded from USD 1.28bn (Jun 25) to USD 13.75bn (Dec 25) on the back of supplier financing arrangements classified as trade AP, then normalised to USD 3.69bn (Mar 26) as suppliers were paid. The cash conversion cycle moved from 86 days (Jun 25) to 54 days (Dec 25) and then to 146 days (Mar 26). The Q3 FY26 operating cash outflow of USD 6.6bn against net income of USD 483m is the largest single-quarter accrual gap in SMCI’s filing history. We view this as a material reset of the underlying working capital intensity of the business.
- On 9 June 2026, management announced a USD 7.0bn equity-linked financing package to fund components for AI orders. The package contains USD 1.25bn underwritten common stock, USD 3.75bn depositary shares representing fractional interests in mandatory convertible preferred stock with automatic conversion in June 2029, and a USD 2.0bn at-the-market (ATM) common stock programme. This is the first SMCI capital raise of FY26 that contains material straight common equity rather than capped-call-protected convertibles. Pro-forma fully diluted dilution from this package alone is approximately 30% on the current basic share count.
- Governance file remains mixed. BDO USA issued clean opinions on the FY24 10-K (filed Feb 2025) and FY25 10-K (filed Aug 2025) with no restatements. Ernst & Young resigned in October 2024. A material weakness in internal controls over financial reporting has been disclosed and is in remediation. The 2020 SEC settlement (USD 17.5m corporate, USD 2.1m personal) found premature revenue recognition under the same management team. The Department of Justice inquiry, first reported September 2024, remains unresolved.
| Period | Net Sales | Net Income | Operating CF | Accrual Gap (NI − OCF) | Cash & Equiv (period-end) |
|---|---|---|---|---|---|
| Q1 FY26 (Sep 30, 2025) | 5,018 | 168 | (918) | (1,086) | 4,197 |
| Q2 FY26 (Dec 31, 2025) | 12,682 | 401 | (42)2 | (443) | 4,091 |
| Q3 FY26 (Mar 31, 2026) | 10,243 | 483 | (6,600) | (7,083) | 1,290 |
| 9M FY26 cumulative | 27,943 | 1,052 | (7,560) | (8,612) | 1,290 |
| FY25 full year (Jun 30, 2025) | 21,972 | 1,049 | ~1,7003 | (651) | 5,170 |
| USD millions. Source: SMCI Form 10-K (28 Aug 2025), Form 10-Qs (7 Nov 2025, 6 Feb 2026, 7 May 2026). 1USD 11.7bn = USD 700m 2028 + USD 1,725m 2029 + USD 2,300m 2030 convertibles + USD 7,000m 9 Jun 2026 announced package. 2Q2 OCF derived as H1 FY26 OCF less Q1 FY26 OCF. 3FY25 OCF concentrated in Q4 (+USD 864m); Q1–Q3 FY25 were weaker. | |||||
| Balance Sheet Item | 30 Jun 2025 | 31 Dec 2025 | 31 Mar 2026 | 9M Δ (vs Jun 25) | 9M Δ % |
|---|---|---|---|---|---|
| Cash & equivalents | 5,170 | 4,091 | 1,290 | (3,880) | (75.0%) |
| Accounts receivable, net | 2,204 | 11,004 | 8,413 | +6,209 | +281.7% |
| Inventories | 4,680 | 10,595 | 11,103 | +6,423 | +137.2% |
| Total current assets | 12,302 | 26,125 | 21,568 | +9,266 | +75.3% |
| Accounts payable | 1,282 | 13,753 | 3,687 | +2,405 | +187.6% |
| Deferred revenue (current) | 369 | 775 | 1,472 | +1,103 | +298.9% |
| Lines of credit + term loans (current) | 75 | 202 | 2,095 | +2,020 | +2,693% |
| Lines of credit + term loans (non-current) | 37 | 21 | 2,019 | +1,982 | +5,357% |
| Convertible notes | 4,645 | 4,655 | 4,659 | +14 | +0.3% |
| Total funded debt | 4,757 | 4,878 | 8,773 | +4,016 | +84.4% |
| Total liabilities | 7,717 | 21,009 | 15,876 | +8,160 | +105.7% |
| Total stockholders’ equity | 6,302 | 6,992 | 7,576 | +1,274 | +20.2% |
| Total assets | 14,018 | 28,002 | 23,452 | +9,434 | +67.3% |
| USD millions. Source: SMCI Form 10-K FY25 and Forms 10-Q for periods ended 31 Dec 2025 and 31 Mar 2026 (exact filed figures, in thousands of USD divided by 1,000). | |||||
| Working Capital Day Metric | 30 Jun 2025 | 31 Dec 2025 | 31 Mar 2026 | 9M Change | LC Observation |
|---|---|---|---|---|---|
| DSO — Days Sales Outstanding | 30 days | 78 days | 74 days | +44 days | AR base 3.8× higher vs. Jun 25; collections lag persists |
| DIO — Days Inventory Outstanding | 81 days | 80 days | 108 days | +27 days | Inventory continuing to build into ~USD 39bn order backlog |
| DPO — Days Payables Outstanding | 25 days | 104 days | 36 days | +11 days | Supplier financing fully unwound; DPO normalised to commercial terms |
| Cash Conversion Cycle | 86 days | 54 days | 146 days | +60 days | CCC has tripled from the Dec 25 print and is 70% higher than the Jun 25 baseline |
| DSO = AR ÷ (quarterly revenue ÷ 90); DPO = AP ÷ (quarterly COGS ÷ 90); DIO = Inventory ÷ (quarterly COGS ÷ 90). CCC = DSO + DIO − DPO. Q3 FY26 quarterly revenue USD 10,243m, COGS USD 9,224m. | |||||
In our view, the cash conversion cycle of 146 days at 31 March 2026 is more representative of the underlying working capital model than the 54-day reading reported at 31 December 2025. The 54-day reading was supported by a USD 13.75bn accounts payable balance representing 104 days of cost of sales — consistent with end-of-period supplier financing facilities (reverse factoring) classified as trade payables rather than as financial debt. As that balance was paid down to USD 3.69bn (36 days, a standard commercial term) during the January–March quarter, the underlying capital intensity of the model emerged. Days inventory outstanding has now reached 108 days, accommodating the USD 39bn AI server backlog management cited in the 9 June 2026 capital announcement.
The financing of the working capital build in Q3 FY26 came from new borrowings, not operations. Funded debt increased by USD 3.9bn between 31 December 2025 and 31 March 2026: current lines of credit and term loans grew from USD 202m to USD 2.10bn, and non-current lines grew from USD 21m to USD 2.02bn. The Q3 FY26 10-Q discloses a USD 2.00bn JPMorgan revolving credit facility and a USD 1.77bn CTBC revolving credit facility put in place to support working capital. The previously disclosed USD 1.79bn Receivables Purchase Agreement remains in place but no receivables had been sold under it as of the filing date.
For peer context, Dell Technologies has historically operated with a negative cash conversion cycle (cash-positive working capital), Hewlett Packard Enterprise has operated at approximately 20–30 days, and Lenovo at 10–15 days. A 146-day CCC at the scale SMCI is now operating, in our view, places considerable pressure on the gross margin profile (Q3 FY26 GAAP gross margin: 9.94%; 9M FY26 GAAP gross margin: 8.18%) given the working capital intensity it implies.
| Instrument | Principal / Balance (USD m) | Coupon | Maturity | Conversion / Settlement | Implied Shares at Conv. |
|---|---|---|---|---|---|
| 2028 Convertible Senior Notes | 700 | 2.25% | 2028 | ~USD 54.00 conv. price (capped call) | ~13.0m |
| 2029 Convertible Senior Notes | 1,725 | Zero coupon | 2029 | ~USD 26.65 (post-split, legacy) | ~64.7m |
| 2030 Convertible Senior Notes | 2,300 | 0.00% | 2030 | USD 55.20 conv. / USD 81.78 capped call | ~41.7m |
| Lines of credit + term loans (current) | 2,095 | Floating | <1 yr | JPM revolver, CTBC lines | n/a |
| Lines of credit + term loans (non-current) | 2,019 | Floating | 1–5 yrs | Bank facilities | n/a |
| Total funded debt at 31 Mar 2026 | 8,773 | — | — | — | ~119m (pre-capped call) |
| Cash & equivalents | (1,290) | — | — | — | — |
| Net debt at 31 Mar 2026 | 7,483 | — | — | — | — |
| USD millions. Source: SMCI Form 10-Q for the period ended 31 Mar 2026. Stockholders’ equity at 31 Mar 2026: USD 7,576m, of which retained earnings USD 4,487m and common stock plus APIC USD 3,088m. | |||||
| Tranche | Size (USD bn) | Instrument | Conversion / Settlement | Dilution Character | Implied Shares1 |
|---|---|---|---|---|---|
| (1) Underwritten common stock | 1.25 | Common stock, single block | Immediate — new shares issued at pricing | Permanent, day-one | ~34m |
| (2) Depositary shares | 3.75 | 1/20th interest in Series A Mandatory Convertible Preferred ($1,000 liquidation pref / share of pref; $50 / depositary share) | Automatic conversion ~1 Jun 2029 — variable number of common shares per conversion rate set at pricing | Permanent. Mandatory — investor has no option to redeem in cash | ~92m2 |
| (3) At-the-market (ATM) programme | 2.00 | Common stock sold directly into the secondary market over time | Continuous, beginning no earlier than Q3 calendar 2026 (Jul–Sep) | Permanent. Open-ended — supply absorbed by float | ~50–57m |
| Total announced 9 Jun 2026 | 7.00 | — | — | — | ~176–183m |
| 1Share-count estimates based on USD 40.64 reference price (closing 9 Jun 2026 prior to announcement); actual issuance prices subject to underwriter discount on the common offering, market pricing through the ATM, and final conversion rate set at pricing for the mandatory preferred. 2Mandatory convertibles typically include a “floor” and “ceiling” conversion ratio — the share count above assumes mid-point conversion; the security is structured to deliver more shares if stock falls below the floor. Stock fell approximately 10% in after-hours trading following the announcement. | |||||
The instrument mix is a step-change from FY25. The June 2025 convertible (USD 2.3bn, 2030 maturity, zero coupon, capped call hedged) was structured to minimise day-one dilution and was specifically described by management as “minimal dilution”. Twelve months later, the new package contains USD 3.25bn of pure common equity (USD 1.25bn underwritten + USD 2.0bn ATM) and USD 3.75bn of mandatory convertible preferred — an instrument that cannot be redeemed in cash and must convert into a variable number of common shares on 1 June 2029. There is no capped call protection on the mandatory preferred tranche. Stock fell approximately 10% in after-hours trading on the day of the announcement (9 June 2026).
| Share Count Step | Shares (millions) | vs. Pre-FY24 Base | vs. 31 Mar 2026 Base | Note |
|---|---|---|---|---|
| Pre-FY24 base (approx. mid-2023) | ~588 | — | — | Pre-2028, 2029, 2030 convert and June 2026 raise |
| Basic shares outstanding 31 Mar 2026 | 601 | +2.2% | — | Mostly RSU vesting and option exercises |
| Diluted weighted average Q3 FY26 (if-converted) | 692 | +17.7% | +15.1% | Existing 2028 / 2029 / 2030 converts in the money |
| + June 2026 underwritten common (USD 1.25bn at ~USD 37) | +34 | — | — | Permanent dilution at execution |
| + June 2026 mandatory preferred (USD 3.75bn, automatic Jun 2029) | +92 | — | — | Mid-point conversion estimate |
| + June 2026 ATM (USD 2.0bn from Q3 2026 onward) | +50–57 | — | — | Issued continuously into the market |
| Pro-forma fully diluted (post-conversion of all instruments) | ~870–875 | +48–49% | +45% | Existing converts + 9 Jun 2026 package fully diluted |
| Pro-forma estimates illustrative only and depend on final issuance prices, mandatory preferred conversion rate set at pricing, and ATM execution prices. Source: SMCI press release 9 Jun 2026; SMCI Forms 10-Q. | ||||
The ATM programme is the most diagnostic element. An at-the-market equity programme is the lowest-quality form of equity capital because it implies the issuer cannot wait for a single marketed block at a negotiated discount, and instead sells stock continuously into the secondary market at prevailing prices. The programme is structured to begin no earlier than calendar Q3 2026, providing a window for market conditions to stabilise but committing the company to continuous dilution thereafter regardless of price action.
The mandatory convertible preferred tranche removes investor optionality on the dilution. Mandatory convertibles, unlike traditional convertible notes, do not give holders the right to redeem at par for cash — conversion into common stock is automatic at the scheduled settlement date. For the USD 3.75bn tranche this means approximately 92 million new common shares will be issued on or around 1 June 2029 regardless of the prevailing stock price or the company’s cash position. The accepted dilution is the cost of receiving cash in the current period.
The stated use of proceeds is component purchase for AI orders, but the arithmetic shows the raise covers only a fraction of the cited backlog. Management cited approximately USD 39bn in AI server orders received from 20+ customers in recent weeks. At the 9M FY26 GAAP gross margin of 8.2%, cost of goods sold for USD 39bn of revenue would total approximately USD 35.8bn. The USD 7.0bn equity raise therefore funds approximately 20% of the COGS required to deliver the cited backlog. The remainder must come from existing cash (USD 1.29bn at 31 Mar 2026, materially lower today), continued use of the USD 4.1bn drawn lines of credit, the USD 1.79bn Receivables Purchase Agreement (currently unused), and/or further capital raises.
Reading across the capital actions of the last twelve months tells a consistent story. In June 2025 management raised USD 2.3bn in zero-coupon convertibles with capped calls, framed as “minimal dilution”. In Q3 FY26 the company drew USD 4bn in new lines of credit. In June 2026 it has announced USD 7.0bn of equity-linked instruments dominated by straight common and mandatory preferred. The instrument mix has moved progressively along the dilution spectrum as the operating cash gap has widened.
| Item | Detail |
|---|---|
| 2020 SEC settlement | SMCI paid USD 17.5m to settle SEC accounting charges including premature revenue recognition (shipments on hold, distributor channel inventory recognised as sales). Charles Liang (CEO/Founder) personally reimbursed USD 2.1m under SOX Section 304 clawback provisions. |
| August 2024 short report | Hindenburg Research published allegations of related-party self-dealing with Ablecom Technology and Compuware Technology (both family-controlled), continued revenue recognition irregularities, and re-hiring of executives previously named in the 2018 SEC investigation. |
| 10-K filing delay | FY24 10-K (period ended 30 Jun 2024) was not filed on time. NASDAQ delisting notice issued. Special committee formed. |
| October 2024 — auditor resignation | Ernst & Young resigned as auditor citing governance, transparency and internal controls concerns. Auditor resignations of this nature at S&P 500-eligible issuers are extraordinarily rare. |
| December 2024 — special committee | Independent Special Committee (Cooley LLP, Forensic Risk Alliance) reported no evidence of fraud or misconduct by management. BDO USA, P.C. engaged as new auditor. |
| February 2025 — delayed filings completed | SMCI filed FY24 10-K and Q1/Q2 FY25 10-Qs. No restatement of prior financial statements. NASDAQ compliance restored. |
| August 2025 — FY25 10-K | Filed on time, clean opinion from BDO. Net sales USD 21.97bn, net income USD 1.05bn. Material weakness in internal control over financial reporting disclosed and in remediation. |
| Department of Justice inquiry | Reported by WSJ in September 2024 as ongoing investigation. No public update on charges or resolution as of the Q3 FY26 10-Q filing in May 2026. |
| Related parties (live disclosure) | Ablecom Technology and Compuware Technology — contract manufacturing partners controlled by Charles Liang’s brothers and spouse. 9M FY26 related-party purchases in COGS: USD 550m (vs USD 492m in 9M FY25). Related-party AP at 31 Mar 2026: USD 134.1m. Audit Committee approval framework in place. |
| Sloan Accrual Diagnostic | 9M FY26 | FY25 | Threshold | Assessment |
|---|---|---|---|---|
| Net Income (USD m) | 1,052 | 1,049 | — | Reported, clean opinion |
| Operating Cash Flow (USD m) | (7,560) | ~1,700 | — | FY25 OCF concentrated in Q4 |
| Accruals = NI − OCF (USD m) | 8,612 | (651) | — | Positive accruals = earnings ahead of cash |
| Total Assets opening (USD m) | 14,018 | — | — | Jun 30, 2025 |
| Total Assets closing (USD m) | 23,452 | 14,018 | — | Mar 31, 2026 / Jun 30, 2025 |
| Average Total Assets (USD m) | 18,735 | ~11,500 | — | Simple average of period-ends |
| Sloan Ratio (Accruals ÷ Avg Assets) | ~46.0% | (5.7%) | Top decile > 10% | 9M reading is in the historic top <1% |
| Sloan (1996, Accounting Review) found high-accruals firms underperformed by approximately 10% annualised over three years and were over-represented in subsequent accounting events. The 10% threshold defines the top accrual decile in the original US large-cap sample. A ~46% reading is materially above any threshold observed in the historic large-cap research universe and is the primary basis for our concern around accruals quality. | ||||
| Beneish Variable | SMCI Reading (Q3 FY26 vs Q3 FY25) | Elevated-Risk Threshold1 | Multiple Over Threshold | Direction |
|---|---|---|---|---|
| DSRI — Days Sales in Receivables Index | ~1.90× (74 / 39 days) | > 1.46 | 1.30× over | Red |
| SGI — Sales Growth Index (Q3 FY26 YoY) | ~2.23× (10,243 / 4,600) | > 1.41 | 1.58× over | Red |
| TATA — Total Accruals to Total Assets | ~0.46 | > 0.018 | 25.6× over | Red |
| GMI — Gross Margin Index (9M FY26 vs 9M FY25) | ~1.17 (11.63% → 8.18% ≡ 1.42× deteriorating)2 | > 1.19 | 0.98× | Borderline neutral |
| AQI — Asset Quality Index | ~1.00 | > 1.04 | 0.96× | Neutral |
| DEPI — Depreciation Index | ~1.00 | > 1.00 | 1.00× | Neutral |
| 1Beneish (1999, Financial Analysts Journal) sample-based thresholds for elevated accounting-risk classification. 2GMI as defined = prior period GM ÷ current period GM. Higher value indicates margin deterioration. SMCI reading is at the threshold border. Three of the six measured inputs are multiples above threshold; the joint distribution of DSRI + SGI + TATA at these levels is statistically associated with the highest-risk band in the original sample, and contributes to our cautious view on the name. | ||||
| TTM Diagnostic (LTM to 31 Mar 2026) | USD m | Per Diluted Share (USD) | Note |
|---|---|---|---|
| TTM Revenue | ~33,700 | — | Trailing four quarters: Q4 FY25 + 9M FY26 |
| TTM Net Income | ~1,247 | ~1.80 | FY25 NI + 9M FY26 NI − 9M FY25 NI |
| TTM Operating Cash Flow | ~(6,700) | ~(9.70) | Trailing four quarters aggregate |
| TTM Capital Expenditure | ~(156) | — | Q1+Q2+Q3 FY26 capex: USD 53.5m + ~USD 25m + USD 97m |
| TTM Free Cash Flow | ~(6,856) | ~(9.93) | OCF less capex |
| TTM Net Income to Free Cash Flow Bridge | (8,103) | — | USD 1.25bn NI does not survive to FCF; gap is USD 8.1bn |
| Source: SMCI Forms 10-K and 10-Q. Capex estimates aggregate disclosed quarterly figures. Free cash flow gap funded by debt drawings and announced 9 Jun 2026 equity-linked raise. | |||
We are not alleging that SMCI’s filings are fraudulent. BDO USA has issued clean opinions on the FY24 and FY25 financial statements. No prior financial statements have been restated. The Cooley LLP / Forensic Risk Alliance independent special committee found no evidence of fraud or misconduct in December 2024. The Department of Justice inquiry reported in September 2024 remains unresolved and unpublished as to outcome. This note expresses Lighthouse Canton’s concerns about accounting practices, cash conversion dynamics and capital structure; it does not assert that any law or accounting standard has been breached.
That said, the filings show what we view as a notably elevated cluster of accruals-based earnings quality indicators relative to US large-cap technology peers. A Sloan accrual ratio of approximately 46%, a cash conversion cycle that has tripled to 146 days once the supplier financing lever reversed, a 9M FY26 free cash flow gap of approximately USD 7.7bn against reported earnings of USD 1.05bn, three Beneish indicators at multiples of threshold, and a 9% gross margin against a 108-day inventory cycle define a profile the academic accounting literature associates with elevated earnings-quality risk.
The 9 June 2026 USD 7.0bn capital announcement, in our reading, is consistent with management’s own assessment of the operating funding gap. The mix shift — from capped-call-protected convertibles (FY25) to USD 3.25bn of straight common equity plus USD 3.75bn of mandatory convertible preferred plus a USD 2.0bn ATM (9 June 2026) — would not, in our view, be the chosen capital structure if the operating model could fund the working capital absorption required by the cited USD 39bn order backlog. The use of a mandatory convertible preferred specifically, with automatic conversion in June 2029 and without capped call protection, accepts a known and pre-committed dilution of approximately 13% on the current basic share count in exchange for current-period cash. The ATM tranche commits to continuous dilution from calendar Q3 2026 onward.
Taken together, the combination of (i) the 2020 SEC accounting violation finding under the same management team, (ii) the October 2024 resignation of a Big Four auditor, (iii) live material related-party contract manufacturing arrangements with family-controlled entities, (iv) a Sloan accrual reading in the historic top <1% percentile, (v) a 146-day cash conversion cycle, (vi) a 9% gross margin profile, and (vii) a USD 7.0bn equity-linked raise sized to fund only a fraction of the components for the stated backlog, forms the basis of Lighthouse Canton’s elevated concern around SMCI’s accounting practices and capital structure. We will continue to monitor disclosures and update our view as facts develop.
Please refer to our full disclaimer for important disclosures and regulatory information. This note expresses Lighthouse Canton’s concerns about accounting practices, cash conversion dynamics and capital structure; it does not assert that any law or accounting standard has been breached.



.png)


